⚙
AI-generated deep summary
by claude@2026-06, 2026-06-07
· read from full text
ⓘ
This narrative review examines evidence for medicinal cannabis in managing endometriosis symptoms, synthesizing proposed mechanisms from animal and human studies, patterns of community use, and findings from clinical trials and observational data. The review reports that although high-quality randomized controlled trial evidence is limited, cross-sectional and retrospective observational studies describe self-reported reductions in endometriosis-related pelvic pain, dysmenorrhea, and gastrointestinal symptoms, alongside improvements in mental health and sleep, with additional discussion of potential safety considerations and drug interactions. A major caveat highlighted is the lack of robust randomized controlled trial data in humans, which prevents strong recommendations for widespread adoption. This paper is centrally about endometriosis — it evaluates whether medicinal cannabis should be used to manage endometriosis symptoms and summarizes the supporting mechanistic and observational evidence.
Abstract
INTRODUCTION: Endometriosis is a chronic inflammatory condition that affects around 1 in 7 women of reproductive age. Current medical treatments tend to be sub-optimal to manage the range of symptoms, with low levels of patient satisfaction. Cross-sectional and retrospective data suggests that people with endometriosis are consuming cannabis to help manage their symptoms.
AREAS COVERED: This review discusses the evidence for consumption of medicinal cannabis to help manage endometriosis symptoms, including potential mechanisms of action from both animal models and human studies, usage in the community, the current evidence from clinical trials and observational studies, and the safety and potential drug interactions.
EXPERT OPINION: While there is a lack of high-quality clinical trial evidence, significant self-reported evidence from cross-sectional surveys and retrospective observational data suggests that those consuming medicinal cannabis report reductions in endometriosis symptoms such as pelvic pain, dysmenorrhea and gastrointestinal symptoms, and improve mental health and sleep. Given the low levels of satisfaction with current treatment options, consideration should be given to trialing medicinal cannabis as part of the interdisciplinary management of endometriosis in those who express interest and who do not demonstrate any significant contraindications.
Full text
3,650 characters
· extracted from
oa-doi-fallback
· click to expand
ABSTRACT
Introduction
Endometriosis is a chronic inflammatory condition that affects around 1 in 7 women of reproductive age. Current medical treatments tend to be sub-optimal to manage the range of symptoms, with low levels of patient satisfaction. Cross-sectional and retrospective data suggests that people with endometriosis are consuming cannabis to help manage their symptoms.
Areas covered
This review discusses the evidence for consumption of medicinal cannabis to help manage endometriosis symptoms, including potential mechanisms of action from both animal models and human studies, usage in the community, the current evidence from clinical trials and observational studies, and the safety and potential drug interactions.
Expert opinion
While there is a lack of high-quality clinical trial evidence, significant self-reported evidence from cross-sectional surveys and retrospective observational data suggests that those consuming medicinal cannabis report reductions in endometriosis symptoms such as pelvic pain, dysmenorrhea and gastrointestinal symptoms, and improve mental health and sleep. Given the low levels of satisfaction with current treatment options, consideration should be given to trialing medicinal cannabis as part of the interdisciplinary management of endometriosis in those who express interest and who do not demonstrate any significant contraindications.
Article highlights
Less than 25% of women with endometriosis report satisfaction with current conventional treatments with high discontinuation rates due to ineffectiveness and side effects.
Dysregulation of the endocannabinoid system in endometriosis, including reduced CB₁ receptors and elevated endocannabinoid levels, provides biological plausibility for therapeutic intervention through TRPV1 modulation and PPARγ activation.
Cannabis consumption is associated with self-reported reductions in pain, gastrointestinal symptoms and nausea, and improvements in sleep quality and mental health.
Cannabis consumption is associated with reductions in potentially addictive medications such as opioids and benzodiazepines; however these reductions should be done under the guidance of a physician.
Despite promising preclinical data and substantial observational evidence, robust randomized controlled trial data in humans remains lacking, preventing recommendation of more widespread adoption as a treatment.
Declaration of interest
M Armour is the principal investigator on several clinical trials on medicinal cannabis and endometriosis; declares grant funding from OzMedicannGroup (OMG), Cannim and Canopy Growth; declares clinical trial products from Australian Natural Therapeutics Group (ANTG); declares consulting fees from Nectar brands, Evolv Health, AIMA and Helius Therapeutics. J Sinclair is employed by ANTG; is a current member of the scientific advisory board for United in Compassion (pro bono); is a board member of the Australian Medicinal Cannabis Association (pro bono). T Farooqi is leading a clinical trial on medicinal cannabis and the gut microbiome in endometriosis and declares clinical trial products from ANTG. C Seaman runs a consultancy for medicinal cannabis. O Holtzman is the vice president of the Australian & New Zealand College of Cannabinoid Practitioners. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.